Annexon Reports Improved Q1 Financials, Extends Cash Runway into H2 2027, and Details ATM Capital Raises
ANNX has more than doubled off its 52-week low of $1.6.
Summary
Annexon, Inc. reported improved Q1 2026 financial results with a reduced net loss and extended its cash runway into the second half of 2027, supported by over $40 million in recent ATM equity sales.
Key Events · Earnings and Guidance · ANNX
-
Improved Q1 Financial Performance
The company reported a net loss of $44.1 million for Q1 2026, an improvement from a $54.4 million net loss in Q1 2025. Basic and diluted net loss per share also improved to $(0.23) from $(0.37) year-over-year.
-
Extended Cash Runway
Management projects that existing cash and cash equivalents and short-term investments of $225.0 million as of March 31, 2026, will fund operating expenses and capital expenditure requirements into the second half of 2027.
-
Significant ATM Capital Raises
Annexon sold 6,049,762 shares for net proceeds of $32.7 million under its 2024 ATM program during Q1 2026. Additionally, subsequent to March 31, 2026, the company sold 1,305,463 shares for $8.1 million under its new $150 million 2026 ATM program.
-
Reduced Operating Cash Burn
Net cash used in operating activities decreased to $46.8 million in Q1 2026 from $50.1 million in Q1 2025, reflecting better expense management.
Analysis · ANNX · Life Sciences
Annexon, Inc. reported a narrower net loss and improved EPS for Q1 2026 compared to the prior year, indicating better financial performance. Critically for a life sciences company, the company has extended its cash runway into the second half of 2027, providing a longer operational horizon. This liquidity was bolstered by significant capital raises through its At-The-Market (ATM) programs, including $32.7 million in Q1 2026 from the now-terminated 2024 ATM program and an additional $8.1 million post-quarter from the new $150 million 2026 ATM program. While these ATM sales are dilutive, they are essential for funding ongoing clinical development, which includes a Marketing Authorization Application (MAA) for tanruprubart in Europe and pivotal data for vonaprument expected in Q4 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANNX was trading at $5.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $897M. The 52-week trading range was $1.60 to $7.18. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.